

Select Long-Acting Insulin Products

Policy # 00728

Original Effective Date: 02/08/2021

Current Effective Date: 10/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider select insulin glargine products including, but not limited to branded insulin glargine-yfgn, branded insulin glargine, Semglee^{TM†} (insulin glargine-yfgn), Rezvoglar^{TM‡} (insulin glargine-aglr), Basaglar[®] (insulin glargine) Kwikpen[®], and branded insulin degludec to be **eligible for coverage**** when the below patient selection criterion is met.

Patient Selection Criteria

Coverage eligibility will be considered for select insulin glargine-products, including but not limited to branded insulin glargine-yfgn, branded insulin glargine, Semglee (insulin glargine-yfgn), Rezvoglar (insulin glargine-aglr), Basaglar (insulin glargine) Kwikpen, and branded insulin degludec when the criteria are met for the requested drug:

- For branded insulin glargine-yfgn, branded insulin glargine, Semglee (insulin glargine-yfgn), Rezvoglar (insulin glargine-aglr), and branded insulin degludec requests:
 - There is clinical evidence or patient history that suggests the use of Lantus^{®‡} (insulin glargine), Toujeo^{®‡} (insulin glargine), or Tresiba^{®‡} (insulin degludec) will be ineffective or cause an adverse reaction to the patient.
- For Basaglar (insulin glargine) Kwikpen requests:
 - There is clinical evidence or patient history that suggests the use of Lantus (insulin glargine) will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of select insulin glargine products, including but not limited to branded insulin glargine-yfgn, branded insulin glargine, Semglee (insulin glargine-yfgn), Rezvoglar (insulin glargine-aglr), and branded insulin degludec when the patient selection criterion is not met to be **not medically necessary.****

Based on review of available data, the Company considers the use of Basaglar (insulin glargine) Kwikpen when the patient selection criterion is not met to be **not medically necessary.****

Select Long-Acting Insulin Products

Policy # 00728

Original Effective Date: 02/08/2021

Current Effective Date: 10/01/2026

Background/Overview

The long acting products mentioned in this policy are approved for both Type 1 and Type 2 diabetes mellitus. Branded insulin glargine-yfgn, Semglee (insulin glargine-yfgn), Rezvoglar (insulin glargine-aglr), Basaglar (insulin glargine) Kwikpen, branded insulin glargine, and Lantus all contain 100 units per mL of insulin glargine. Toujeo contains 300 units per mL of insulin glargine. Tresiba and branded insulin degludec contain either 100 or 200 units per mL of insulin degludec.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

The patient selection criteria presented in this policy take into consideration clinical evidence or patient history that suggests the use of Lantus, Toujeo, or Tresiba will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above-mentioned caveat, there is no advantage of using branded insulin glargine-yfgn, branded insulin glargine, Semglee (insulin glargine-yfgn), Rezvoglar (insulin glargine-aglr), or branded insulin degludec over Lantus, Toujeo, or Tresiba, nor is there an advantage of using Basaglar (insulin glargine) over Lantus.

References

1. Semglee [package insert]. Mylan Pharmaceuticals. Morgantown, West Virginia. Updated June 2020.
2. Lantus [package insert]. Sanofi-Aventis. Bridgewater, New Jersey. Updated November 2019.
3. Toujeo [package insert]. Sanofi-Aventis. Bridgewater, New Jersey. Updated November 2019.
4. Tresiba [package insert]. Novo Nordisk. Plainsboro, New Jersey. Updated December 2019.
5. insulin glargine-yfgn [package insert]. Mylan Pharmaceuticals. Morgantown, West Virginia. Updated July 2021.
6. Insulin glargine [package insert]. Winthrop U.S. Bridgewater, New Jersey. Updated January 2021.
7. Insulin degludec [package insert]. Novo Nordisk. Plainsboro, New Jersey. Updated July 2022.
8. Rezvoglar [package insert]. Eli Lilly and Company. Indianapolis, Indiana. Updated November 2022.
9. Basaglar Kwikpen [package insert]. Eli Lilly and Company. Indianapolis, Indiana. Updated July 2021.

Policy History

Original Effective Date: 02/08/2021

Current Effective Date: 10/01/2026

01/07/2021 Medical Policy Committee review

01/13/2021 Medical Policy Implementation Committee approval. New policy.

01/06/2022 Medical Policy Committee review

Select Long-Acting Insulin Products

Policy # 00728

Original Effective Date: 02/08/2021

Current Effective Date: 10/01/2026

01/12/2022	Medical Policy Implementation Committee approval. No change to coverage.
02/03/2022	Medical Policy Committee review
02/09/2022	Medical Policy Implementation Committee approval. Added insulin glargine-yfgn to the policy. Changed the title of the policy from Semglee (insulin glargine) to insulin glargine-yfgn (Semglee, biosimilar).
08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Changed title of policy from insulin glargine-yfgn (Semglee, biosimilar) to Select insulin glargine Products. Updated product list to read as branded insulin glargine-yfgn, branded insulin glargine, and branded Semglee-yfgn.
03/02/2023	Medical Policy Committee review
03/08/2023	Medical Policy Implementation Committee approval. Change title from “Select insulin glargine Products” to “Select Long-Acting Insulin Products.” Added branded insulin degludec to policy.
10/05/2023	Medical Policy Committee review
10/11/2023	Medical Policy Implementation Committee approval. Edited policy to delete “branded” from Semglee (insulin glargine-yfgn). Added new drug, Rezvoglar, to the policy.
10/03/2024	Medical Policy Committee review
10/08/2024	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/02/2025	Medical Policy Committee review
10/08/2025	Medical Policy Implementation Committee approval. Added Basaglar Kwikpen to the policy with relevant criterion and background information. Removed Levemir from the policy due to its discontinuation.
09/09/2026	Pre Pharmacy & Therapeutics Committee review.
09/16/2026	Pharmacy & Therapeutics Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 09/2027

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

Select Long-Acting Insulin Products

Policy # 00728

Original Effective Date: 02/08/2021

Current Effective Date: 10/01/2026

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.